(to normal or by >15%7) coupled with a rise in pH by -0.05. Using this definition, there were eight responders (67%) and four nonresponders (33%). The responders had a shorter duration of symptoms (17.8 vs 78.0 h, p<0.05) and a lower preheliox pH (7.20 vs 7.30, p<0.05). All of the responders presented within 24 h of symptom onset. Three of the four nonresponders reported prolonged (-96 h) duration of symptoms, and two eventually required intubation. Conclusion: Heliox can rapidly improve ventilation in patients presenting to an emergency department with acute severe asthma with respiratory acidosis and a short duration of symptoms. (Chest 1995; 107:757-60) ABGs=arterial blood gases; heliox=helium-oxygen Key words: asthma; heliox; helium; respiratory acidosis; status asthmaticus turbulent flow are converted to laminar flow. The reduction in airway resistance results in a decreased work of breathing.
Barachl in 1935 was the first to use helium to improve air flow in patients with airways obstruction, but it was soon cast aside for other treatment modalities. Since then, it has been relegated mainly For editorial comment see page 597 to use in upper airway obstruction or to diagnostic studies.2-6 Safety and efficacy have been demonstrated for both spontaneously breathing patients7 and for intubated patients receiving mechanical ventilation,8 but its therapeutic potential has not been fully explored.
Helium has no bronchodilating or anti-inflammatory properties and in fact is quite inert. Since airway resistance in turbulent flow is directly related to the density of the gas, helium, with its lower density than nitrogen or oxygen, results in lower airway resistance. Helium further lowers airway resistance by reducing the Reynolds number, such that some areas of 
RESULTS
For the entire group (n =12), institution of heliox was associated with a drop in PaCO2 from 57.9 ± 8.3 mm Hg to 47.5 ±4.3 mm Hg (p<0.005) (Fig 1) and Pre-Heliox Heliox A clinically significant response to heliox was defined prior to data analysis as either normalization of PaCO2 (defined as a PaCO2 <45 mm Hg) or a 215% drop in PaCO2, either of which had to be coupled with an increase in pH of -0.05. By this definition, there were eight responders, seven of whom had a >15% decrease in PaCO2, and one of whom had a normalization of the PaCO2 to 41 mm Hg. There were four nonresponders. None of the nonresponders had more than a 10% drop in PaCO2 and none lowered the PaCO2 to <45 mm Hg.
Characteristics of the responders and the nonresponders were examined. The responders had a significantly lower preheliox pH (7.20 ± 0.06 vs 7.30±0.03, p<0.05) and a significantly shorter duration of symptoms at time of presentation (17.8 ± 8.9 h vs 78 ± 36 h, p<0.05) ( Table 1 ). The small sample size prevented logistic regression analysis to determine whether initial pH or duration of symptoms was a more important predictor of a response to heliox. All responders (eight of eight) presented with an acute (<24 h) exacerbation of symptoms. Three of the four nonresponders presented -96 h after onset of symptoms (Figs 1 and 2 ). There were no significant differences (p>O.1) between the groups in the number of nebulized albuterol treatments or the number of patients who had received subcutaneous terbutaline, maintenance oral theophylline, or intravenous aminophylline. Although length of stay in the intensive care unit was not significantly different between the two groups (responders, 1.3±1.1 days, vs nonresponders, 3.1 ± 3.3 days; p=0.359), the responders had a significantly shorter hospital length of stay (3.8 ± 1.9 days vs 7.3 ±3.2 days, p<0.05).
Three of the seven patients who started heliox via face mask had symptoms for >96 h, and two of them ended up being intubated. The other four had symptoms for <24 h, and none required intubation. In the present study, the conditions of all of the patients were sufficiently improved after 24 h for heliox therapy to be discontinued without clinical deterioration. DISCUSSION This study showed that heliox can cause an acute improvement in respiratory acidosis in patients with severe asthma. The rapidity of improvement with heliox inhalation strongly suggests a direct beneficial relationship, although the lack of a control group raises the possibility that this improvement was due to the delayed effects of previously administered therapies. Patients with a shorter duration of symptoms were much more likely to respond to heliox therapy. In this subset of patients, heliox improves respiratory acidosis by decreasing airway resistance and consequently the work of breathing. In those who respond to helium given via mask, intubation and mechanical ventilation may be prevented. Heliox thus serves as a therapeutic bridge for the 6-to 12-h interval from patient arrival in the emergency department until corticosteroid impact.10 Conversely, failure of asthmatics with hypercapnia and respiratory acidosis to respond to heliox therapy given via mask might herald a failure to respond to aggressive treatment and thus indicate an increased risk for intubation and mechanical ventilation.
Asthmatics with hypercapnia and respiratory acidosis unresponsive to medical therapy may require mechanical ventilation. Although the initiation of mechanical ventilation in patients with intractable severe asthma may save lives, it is associated with increased morbidity.1' Intubation and mechanical ventilation may actually increase the risk of death in some patients with severe asthma.12 Heliox may sometimes eliminate the need for intubation and mechanical ventilation, obviating this dilemma. Heliox benefits the intubated asthmatic, as its use allows adequate ventilation with reduced pressures, thereby decreasing the risk of barotrauma.8
In conclusion, heliox rapidly improves ventilation in patients presenting to an emergency department with acute severe asthma with respiratory acidosis and a short duration of symptoms.
